Hansa Biopharma has won the 2025 SwedenBIO Award

Rhea-AI Summary

Hansa Biopharma (NASDAQ: HNSA) won the 2025 SwedenBIO Award, presented at the SwedenBIO Summit in Stockholm on 21 January 2026. The award recognized Hansa for converting Swedish scientific excellence into global medical impact, building commercial capabilities for global markets, and advancing enzyme technology that enables transplantation for highly sensitized patients.

The company noted strong clinical progress, referencing U.S. Phase 3 data, an upcoming FDA review process, and an anticipated European Phase 3 readout later in 2026. CEO Renée Aguiar-Lucander said the award reflects momentum heading into 2026 and honored the Hansa team.

Key Figures

Award year: 2025 Award inception: 2007 Announcement date: Jan. 22, 2026 +2 more

5 metrics

Award year 2025 SwedenBIO Award designation year

Award inception 2007 Year SwedenBIO Award was established

Announcement date Jan. 22, 2026 Press release date

U.S. trial phase Phase 3 Strong U.S. Phase 3 data mentioned

European trial phase Phase 3 Anticipated Phase 3 readout from European trial

Market Reality Check

normal vol

Market Pulse Summary

This announcement highlights external validation for Hansa Biopharma via the 2025 SwedenBIO Award an...

Analysis

This announcement highlights external validation for Hansa Biopharma via the 2025 SwedenBIO Award and emphasizes progress in its pipeline, including strong U.S. Phase 3 data, an upcoming FDA review process, and an anticipated European Phase 3 readout in 2026. Investors may track the timing and outcomes of these regulatory and clinical milestones, as well as how the company translates its enzyme technology into broader commercial adoption.

Key Terms

phase 3, fda review process, phase 3 trial, clinical results, +1 more

5 terms

phase 3 medical

"powered by our strong U.S. Phase 3 data, the upcoming FDA review process"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

fda review process regulatory

"powered by our strong U.S. Phase 3 data, the upcoming FDA review process"

The FDA review process is the official U.S. government evaluation of a drug, biologic or medical device that examines clinical results, safety, manufacturing quality and labeling before the product can be marketed. Investors treat it like a final inspection and gatekeeper: a positive outcome clears the way for sales and revenue, while delays, requests for more data or a denial can push back launch dates, raise costs and materially change a product’s commercial prospects and risk.

phase 3 trial medical

"and the anticipated Phase 3 readout from our European Phase 3 trial later this year"

A Phase 3 trial is a large, late-stage test of a new drug or medical treatment done on many people to make sure it really works and is safe. For investors, it matters because a successful Phase 3 usually means the company can ask regulators to sell the product and could earn lots of money, while failure can sharply reduce the company’s value.

clinical results medical

"By advancing breakthrough innovation and delivering strong clinical results, the company strengthens Sweden's position"

Clinical results are the measured outcomes from tests of a medical treatment or diagnostic on people, showing how well it works and whether it is safe. For investors, these results act like performance reports from a product trial — strong results can increase the chance of regulatory approval, market acceptance, and future revenue, while weak or unclear results raise the risk of delay, additional testing, or failure.

transplantation medical

"Hansa enables life-saving transplantation for highly sensitized patients with previously unmet needs"

Transplantation is the medical procedure of replacing a failing or absent organ, tissue, or cells with healthy ones from a donor or from another part of the patient’s body; think of swapping a broken part in a machine to restore function. It matters to investors because transplants drive demand for surgical services, specialized drugs, medical devices and long‑term care, influence regulatory approvals and reimbursement policies, and can materially affect the revenues and risks of healthcare companies involved in transplant technology and follow‑up care.

AI-generated analysis. Not financial advice.

LUND, Sweden, Jan. 22, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The award was presented at the SwedenBIO Summit in Stockholm on 21 January, where Hansa was selected as the winner among the many nominated companies.

Since its inception in 2007, the SwedenBIO Award has celebrated companies that drive meaningful scientific progress, operational excellence, and international impact. This year's motivation highlights Hansa Biopharma for transforming Swedish scientific excellence into global medical impact and serving as a bold guiding star in building commercial capabilities for global markets. Through its pioneering enzyme technology, Hansa enables life-saving transplantation for highly sensitized patients with previously unmet needs. By advancing breakthrough innovation and delivering strong clinical results, the company strengthens Sweden's position as a leader in life science innovation.

Renée Aguiar-Lucander, CEO, Hansa Biopharma said,  "I am truly delighted and deeply honored to receive this award on behalf of everyone at Hansa Biopharma. This recognition reflects the great momentum we've built heading into 2026—powered by our strong U.S. Phase 3 data, the upcoming FDA review process, and the anticipated Phase 3 readout from our European Phase 3 trial later this year. Thank you to the SwedenBIO organization and judges for this recognition. We're proud of how far we've come, and excited for the journey ahead."

Contacts for more information:

Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com 

Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com 

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform to address serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-has-won-the-2025-swedenbio-award,c4296348

The following files are available for download:

https://mb.cision.com/Main/1219/4296348/3892443.pdf

2026-01-22 SwedenBio Award

 

View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-has-won-the-2025-swedenbio-award-302668060.html

SOURCE Hansa Biopharma AB

FAQ

What did Hansa Biopharma (HNSA) win on January 21, 2026?

Hansa won the 2025 SwedenBIO Award at the SwedenBIO Summit in Stockholm on 21 January 2026.

Why did Hansa Biopharma (HNSA) receive the 2025 SwedenBIO Award?

The award cited Hansa's translation of Swedish scientific excellence into global medical impact, commercial capability building, and pioneering enzyme technology for transplantation.

What clinical milestones did Hansa mention along with the SwedenBIO Award?

Hansa referenced strong U.S. Phase 3 data, an upcoming FDA review process, and an anticipated European Phase 3 readout later in 2026.

Where and when was the SwedenBIO Award presented to Hansa (HNSA)?

The award was presented at the SwedenBIO Summit in Stockholm on 21 January 2026.

Who commented for Hansa Biopharma after receiving the SwedenBIO Award?

CEO Renée Aguiar-Lucander commented that the award reflects momentum heading into 2026 and thanked SwedenBIO and the judges.